NCT02736955View on ClinicalTrials.gov

Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia

PHASE3CompletedINTERVENTIONAL
Enrollment

161

Participants

Timeline

Start Date

June 13, 2016

Primary Completion Date

June 30, 2017

Study Completion Date

June 30, 2017

Conditions
Tardive Dyskinesia
Interventions
DRUG

Valbenazine

Trial Locations (27)

Unknown

Anaheim

National City

Norwalk

Oakland

San Bernardino

San Diego

Torrance

Hialeah

North Miami

Orlando

Chicago

Shreveport

Worcester

Cedarhurst

Dayton

Shaker Heights

Oklahoma City

Norristown

Charleston

Franklin

Memphis

DeSoto

Fort Worth

Irving

Salt Lake City

Petersburg

Spokane

Sponsors
All Listed Sponsors
lead

Neurocrine Biosciences

INDUSTRY